Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes
The Eurasian Patent Office has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of individuals with type 1 diabetes carrying the HLA DR4-DQ8 genetic marker will be granted. The patent is valid until 2038.The forthcoming Eurasian patent grant strengthens Diamyd Medical’s intellectual property portfolio, building on the established foundation for patients with the HLA DR3-DQ2 haplotype — a distinct genetic subgroup currently targeted by the company’s investigational GAD-specific immunotherapy, Diamyd[®], in the ongoing Phase 3